Joint Corp. lowers 2025 system-wide sales outlook to $530M-$550M

Lowered from $550M-$570M. The company’s consolidated adjusted EBITDA has been increased to $10.8M to $11.8M versus prior guidance of $10.0M to $11.5M. New franchised clinic openings, excluding the impact of refranchised clinics, are now expected to be in the range of 30 to 35, compared to 57 in 2024. The company said, “In light of softer sales trends coupled with macro headwinds, the company is taking a balanced view of the remainder of the year and is revising 2025 guidance.”